The Call @ Hedgeye | August 11, 2022

Watch below as Healthcare analyst Tom Tobin  highlights Natera (NTRA), then discusses cancer testing and then comments on the Delta Variant.  

(This clip is a small taste of what our subscribers get each day on The Call @ Hedgeye. In a nutshell, The Call is our morning research call hosted by Hedgeye CEO Keith McCullough with our 40+ analyst research team. It helps small and large investors alike make better decisions via unique and investable stock/sector updates Click here to learn more.)